Effectiveness of palivizumab: Evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season

Pediatric Infectious Disease Journal

Volumn 19, Issue 11, 2000, Pages 1068-1071

  Sorrentino, Mark ^a   Powers, Tonya ^a  

^a MEDIMMUNE   (United States)

Author keywords

Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD; CHILD HOSPITALIZATION; CHRONIC LUNG DISEASE; COMORBIDITY; DRUG EFFICACY; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROSPECTIVE STUDY; RNA VIRUS INFECTION; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE; PATIENT COMPLIANCE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 0033710257     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200011000-00007     Document Type: Article

References (13)

1. Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: Still no answer
2. Bronchiolitis associated hospitalizations among children, 1980-1996
3. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children
4. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants
5. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
6. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
7. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
8. Rehospitalization for respiratory illness in infants of less then 32 weeks' gestation
9. The continuing morbidity and use of health services by preterm infants after discharge from hospital
10. Birth weight and hospital readmission of infants born prematurely
11. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: Potential for savings
12. Prevention of respiratory syncytial virus infections indications for the use of palivizumab and update on the use of RSV-IGIV
13. First year experience using palivizumab humanized monoclonal antibody for protection from RSV lower respiratory tract infection